Clinical Research Center (CRC), Bldng 60:11
Malmö, 20502, Sweden
NCT Number: NCT03562221
This study aims to investigate the impact of being on a gluten free diet the first three years of life compared to a daily intake of a probiotic supplementation or placebo on the risk of developing celiac disease autoimmunity or celiac disease in genetically susceptible children.
This is a three-arm (1:1:1) randomized trial where study participants are randomly allocated to one of the three study groups before the age of 4 months. Regular clinical visits (4 times/year) during the intervention phase and yearly there after, up to the age of 7 years.
This study is active but is not currently recruiting participants.
4 month–4 month
All sexes
Interventional
Not applicable
Malmö, 20502, Sweden
The primary hypothesis to be tested is that a strictly gluten free diet during the first three years of life with a slow introduction of gluten during the follow-up period will induce tolerance to gluten. A similar hypothesis is tested if a daily supply of two different lactobacillus (LB) strains can suppress an inflammatory response to gluten in the intestine by stimulating regulatory T-cells and reduced permeability of gluten peptides in the intestine.
The secondary hypothesis tested is that celiac disease can not be prevented, but the onset of the disease will be delayed in children returning to a gluten-containing diet after the intervention period (gluten free diet) or probiotic treatment) during the first three years of life. The intervention period is 3 years and the follow-up period is further 4 years.
The primary aim is to study the proportion of children who develop celiac disease autoimmunity and progression to celiac disease by the age of 3 years. Secondary aim is to study the proportion of children who developed celiac disease at the age of 7 years.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Controlled gluten free diet
Capsules
Capsules
Time frame: from 4 months of age up until 7 years of age
Radioligand binding assays (RBA) will be used to measure tTG autoantibodies in serum samples collected every third months up until the age of 3 years and then annually up until the age of 7 years.
Time frame: Up until 7 years of age
A celiac disease diagnose will be defined by an intestinal biopsy showing a Marsh score of 2 or higher or by high levels of tTG autoantibodies (> 100 units) in at least 2 consecutive blood samples.
Lund University
Other
Prevention of Celiac Disease in Skåne (in Swedish - Prevention av Celiaki i Skåne)
Acronym: PreCiSe
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05548166
Celiac Disease, Celiac Disease in Children
Hamilton, Ontario, Canada
View Trial DetailsNCT06038344
Adherence, Treatment, Behavior
Edmonton, Alberta, Canada
View Trial DetailsNCT06206616
Celiac Disease, Celiac Disease in Children
Palermo, Italy
View Trial DetailsNCT07382999
Celiac Disease, Celiac Disease in Adolescents
Malatya, Turkey (Türkiye)
View Trial Details